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We report a mechanism to induce combined and long-lived CD4ⴙ and CD8ⴙ T cell immunity
to several mouse tumors. Surprisingly, the initial source of antigen is a single low dose of
tumor cells loaded with ␣-galactosylceramide (␣-GalCer) glycolipid (tumor/Gal) but lacking
co-stimulatory molecules. After tumor/Gal injection intravenously (i.v.), innate NKT and NK
cells reject the tumor cells, some of which are taken up by dendritic cells (DCs). The DCs in
turn cross-present glycolipid on CD1d molecules to NKT cells and undergo maturation. For
B16 melanoma cells loaded with ␣-GalCer (B16/Gal), interferon ␥–producing CD8ⴙ T cells
develop toward several melanoma peptides, again after a single low i.v. dose of B16/Gal. In
all four poorly immunogenic tumors tested, a single dose of tumor/Gal i.v. allows mice to
become resistant to tumors given subcutaneously. Resistance requires CD4ⴙ and CD8ⴙ cells,
as well as DCs, and persists for 6–12 mo. Therefore, several immunogenic features of DCs
are engaged by the CD1d-mediated cross-presentation of glycolipid-loaded tumor cells,
leading to particularly strong and long-lived adaptive immunity.
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A major challenge to tumor immunology is to
identify and elicit protective mechanisms that
parallel the more powerful immune responses
that are seen in other settings, such as resistance
to infection and rejection of transplants (1).
However, it has been difficult to induce strong
immunity to tumors, particularly T cells that
recognize multiple antigens in tumor cells and
differentiate to express helper and killer functions, as well as memory.
One way to improve T cell–based resistance
to tumors is to expand tumor-reactive lymphocytes to large numbers ex vivo and then reinfuse
them back into patients. Measurable resistance
develops after such passive immunotherapy
with CD8⫹ T cells in humans (2–4). Another
approach is the active induction of resistance
to tumors in vivo. Certain chemotherapies can
elicit some immunity to tumors, because the
dying tumor cell is both recognized by DCs and
matures the DCs to induce immunity, although
The online version of this article contains supplemental material.
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the tumor resistance is partial (5, 6). Stronger
resistance can be induced when DCs take up
irradiated tumor cells injected i.v.; then, the
DCs are matured through activated NKT lymphocytes or by a combination of an agonistic
anti-CD40 antibody and a ligand for Toll-like
receptors (7). However, this pathway requires
large numbers of tumor cells, which for some
tumors like the B16 melanoma, is toxic. It is
important to identify pathways that allow tumor
cells to more efficiently induce long-lived, specific, T cell–mediated immunity.
In this paper, we report a mechanism that
induces potent T cell immunity to several poorly
immunogenic, transplantable mouse tumors,
including the B16 melanoma. The mechanism
depends on the capacity of DCs in the spleen
to take up and cross-present dying cells (8).
Previous research has emphasized the crosspresentation of protein antigens onto MHC class I
products permitting the generation of CD8⫹
killer T cells (7, 9). We now describe the crosspresentation of glycolipids on CD1d molecules
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RESULTS
Vaccination with B16 melanoma cells loaded with ␣-GalCer
(B16/Gal) induces T cell–dependent antitumor resistance
The mouse B16 melanoma expresses little or no MHC products or co-stimulatory molecules (e.g., CD40 and CD86)
and is poorly immunogenic. When injected s.c. into syngeneic
C57BL/6 mice, it grows rapidly and overcomes all animals
(Fig. 1 A). We evaluated whether protection against B16 could

be induced by an injection of DCs loaded with ␣-GalCer
(DC/Gal), because we had reported that DC/Gal can activate NK and NKT cells and protect against metastasis of
i.v.-injected B16 to the lung (12, 13). However, mice given
DC/Gal did not protect against B16 challenge s.c. (Fig. 1 A)
or challenge with EL4 thymoma s.c. (not depicted). This was
also the case for s.c.-injected B16/Gal and with tumor cells
that had been transfected to express high levels of CD1d and
loaded with ␣-GalCer (CD1dhi-B16/Gal; Fig. 1 B).
Unexpectedly, if we first injected mice with live B16/Gal
i.v. and then challenged the mice with B16 tumor cells
s.c. 2 wk later, 6 out of 10 animals now showed resistance
(Fig. 1 C). If we injected transfected CD1dhi-B16/Gal i.v., all
the mice became resistant to a challenge with B16 tumor s.c
(Fig. 1 D, left). This resistance proved to be T cell mediated.
Thus, CD4⫺/⫺ and CD8⫺/⫺ mice did not develop resistance
to a subsequent s.c. challenge with B16 tumor cells (Fig. 1 D,
right), although the knockout mice effectively resisted the
growth of the initial inoculum of living CD1dhi-B16/Gal
tumor cells given i.v. by innate mechanisms, as shown previously (11). The finding that lung metastases were still inhibited when B16/Gal or CD1dhi-B16/Gal were administered

Figure 1. Vaccination with B16/Gal induces T cell–dependent antitumor resistance. (A) 106 ␣-GalCer–loaded DCs per mouse were administered
to mice. 105 B16 melanoma tumor cells were injected s.c. 2 wk later. Measurement of tumor size was done at the indicated time points (n ⫽ 5 per group).
Similar results were obtained in two independent experiments. (B) 105 B16/Gal or nonloaded B16 melanoma cells per mouse were administered s.c., and
tumor size was followed (n ⫽ 5 per group). Similar results were obtained in two independent experiments. (C and D, left) 5 ⫻ 105 ␣-GalCer–loaded B16
or CD1dhi-B16 tumor cells per mouse were given i.v., and 2 wk later mice were challenged with 105 parental B16 tumors s.c. (n ⫽ 10 per group). Similar
results were obtained in two independent experiments. (D, right) At 2 wk after vaccination of CD4⫺/⫺, CD8⫺/⫺, and MHC II⫺/⫺ mice with 5 ⫻ 105 CD1dhiB16/Gal i.v., the mice were challenged s.c. with B16 tumor cells (n ⫽ 5 per group). Similar results were obtained in two independent experiments.
(E) CD19⫹ B cells were isolated with magnetic beads from the spleen, coated with ␣-GalCer, and injected together with irradiated CD1dhi-B16 cells (n ⫽ 5
per group). Data are means ⫾ SEM. Similar results were obtained in two independent experiments.
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in vivo. Cross-presentation of glycolipids has been noted in
one previous study in tissue culture (10), but in vivo consequences could not be assessed. We find that the i.v. administration of either live or irradiated tumor cells, which have
been loaded with the agonistic glycolipid ␣-galactosylceramide (␣-GalCer), first elicits an innate NKT and NK cell
response that rejects the tumor, including cells that have been
administered 3 d previously (11). This approach, even though
it involves a single low dose of tumor cells lacking in costimulatory molecules, leads to a second NKT cell response
to glycolipid cross-presented by DCs. The DCs then mature
and induce combined CD4⫹ and CD8⫹ protective T cell immunity to the captured tumor cells.

ARTICLE

resistance of CD4⫺/⫺ mice to tumor administered s.c. differs
from our previous study showing innate resistance to ␣-GalCer–
loaded tumor cells given i.v. (11). With the i.v. route, transplantable tumors, including B16 melanoma, are rejected
by innate NKT cells (especially CD4⫺ NKT cells) and NK
cells without the need for adaptive CD4⫹ or CD8⫹ T cell
immunity (11). Collectively, the results, which show the
induction of protective T cell immunity to B16 melanoma,
were surprising because it has been so difficult to raise T cell
responses to this tumor, especially with a single and low dose
of tumor cells.
Finally, to demonstrate that the ␣-GalCer needed to be
loaded on the tumor cells and could not be transferred from
or induced by ␣-GalCer on other cells, we injected a mixture
of ␣-GalCer–loaded, splenic B cells plus irradiated CD1dhiB16 cells that were not loaded with ␣-GalCer. Mice given
irradiated CD1dhi-B16 cells alone did not develop resistance,
and this was also the case when mice were given ␣-GalCer–
loaded B cells plus irradiated CD1dhi-B16 cells (Fig. 1 E).
The latter data indicate that ␣-GalCer does not elute in sufficient amounts to coat CD1dhi-B16 cells, in contrast to tumor

Figure 2. Vaccination with B16-GalCer tumor cells i.v. leads to T cell immunity to several defined melanoma differentiation antigens.
(A) Mice were injected i.v. with 5 ⫻ 105 B16, B16/Gal, CD1dhi-B16, or CD1dhi-B16/Gal. To monitor antigen-specific T cell responses 1 and 4 wk later, CD8⫹
T cells were positively selected from the spleen and were cultured with splenic CD11c⫹ DCs from naive mice for 36 h. The DCs had been cultured for 2 h in
the presence or absence of 10 M gp10025–33, Trp2180–188, Tyrp455–463, Tyrp522–529, or Dct363–371 peptides. T cells responding to the DCs were detected by
ELISPOT assay for IFN-␥ production. All data are means ⫾ SEM obtained from three independent experiments with two mice per group. *, P ⬍ 0.05 for
B16/G versus CD1dhi-B16/G. (B) As in A, but the immune responses were monitored with intracellular cytokine staining. CD8⫹ T cells were magnetically
isolated from the spleen 7 d after i.v. CD1dhi-B16/Gal. The CD8⫹ T cells were co-cultured for 16 h with splenic CD11c⫹ DCs from naive mice in the presence of brefeldin A, which had been pulsed with 10 M Trp2180–188 peptide for 2 h, for the last 10 h. Numbers indicate the percentage of total CD8⫹ cells.
The data are representative of three independent experiments (n ⫽ 4 per group). (C) Mice were immunized with 5 ⫻ 105 CD1dhi-B16/Gal and depleted
NK1.1⫹ cells by injections of 300 g of anti-NK1.1(PK136) antibody per mouse at days −1, 3, and 5 (before vaccination), or days 3 and 5 (after vaccination).
As in A, the TRP2-specific CD8⫹ T cell response was detected by ELISPOT assay for IFN-␥ at day 7. Data are means ⫾ SEM obtained from three independent
experiments (n ⫽ 4 per group). **, P ⬍ 0.01.
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to CD4⫺/⫺ mice was surprising, in that CD4⫹ NKT cells
seemed dispensable for providing innate immunity. The
data may be consistent with Crowe et al., who reported
that CD4⫺ NKT cells showed stronger antitumor immunity
than CD4⫹ NKT cells (14). However, CD4⫺ NKT cells in
CD4⫺/⫺ mice may include cells that are equivalent to CD4⫹
NKT cells in WT mice. Therefore, we also tested whether
antitumor effects develop in MHC II⫺/⫺ mice that would
not have conventional CD4⫹ T cells. Fig. S1 (available at
http://www.jem.org/cgi/content/full/jem.20070458/DC1)
shows that MHC II⫺/⫺ mice had CD4⫹ CD1d-dimer⫹ NKT
cells and some CD4⫹ CD1d-dimer⫺ T cells (15, 16). The
latter may include T cells that are not MHC II restricted,
as well as some type 2 NKT cells or MR1-restricted cells.
When we gave tumor cells loaded with ␣-GalCer (tumor/Gal)
to MHC II⫺/⫺ mice, resistance to B16 melanoma did not
develop (Fig. 1 D, right), although the mice showed delayed rejection of ⵑ1 wk, presumably caused by the residual
CD4⫹ T cells (Fig. S1). In contrast, as shown in Fig. 1 D,
CD4⫹ T cells were required to induce adaptive antitumor
immunity to s.c. challenge with tumor. The lack of adaptive
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Figure 3. Vaccination with live and irradiated tumor/Gal induces antitumor protection against several mouse tumors. (A, left) Immunization
experiments were set up as shown; i.e., mice were vaccinated with 5 ⫻ 106 of different forms of J558 myeloma cells, challenged at 4 wk with 106 live
J558 s.c., and evaluated for their survival (n ⫽ 10 per group). Similar results were obtained in two independent experiments. (B) Mice were injected i.v.
with 5 ⫻ 105 live and irradiated CD1dhi-B16/Gal (n ⫽ 9 and 6 per group, respectively), 2 ⫻ 106 CD1dhi-WEHI-3B/Gal (n ⫽ 5 per group), or 5 ⫻ 105
CD1dhi-EL4/Gal (n ⫽ 8 and 5 per group, respectively). The mice were challenged s.c. with parental tumor cells (5 ⫻ 104 B16, 2 ⫻ 105 WEHI-3B, or 2 ⫻ 105
EL4) 4 wk later. Tumor sizes were measured at the indicated time points. Similar results were obtained in two independent experiments. (C) Mice were
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cells directly loaded with ␣-GalCer (Fig. 1 D). Collectively,
the results in Fig. 1 indicate that ␣-GalCer–loaded tumor
cells in relatively small numbers are able to induce T cell resistance to an s.c. challenge with B16 melanoma.

Several ␣-GalCer–loaded tumors injected i.v. establish
resistance to native tumor
To extend the analysis to other tumors, we studied the J558
plasmacytoma. J558 also grew rapidly when injected s.c., and
the mice did not survive (Fig. 3 A, open squares). However,
if we first injected the tumor or its CD1d transfectant i.v.
(each loaded with ␣-GalCer), then the animals developed
resistance to an otherwise lethal s.c. challenge with J558
(Fig. 3 A). We next compared the B16 melanoma in Figs.
1 and 2 with the EL4 thymoma and WEHI-3B acute myelomonocytic leukemia, each of which grew aggressively in
mice after s.c. inoculation (Fig. 3 B). We had previously
shown that these ␣-GalCer–coated tumors elicited strong NKT
cell–dependent innate resistance (11). 4 wk after injecting
␣-GalCer–loaded, live, or irradiated CD1dhi tumors i.v., we

␣-GalCer–loaded tumor cells are superior inducers of T cell
immunity to DCs injected i.v.
Because the immune response to a single dose of co-stimulator–
poor tumor/Gal was strong relative to the existing literature,
we further compared tumor/Gal with DC/Gal. OVA was
used as a surrogate antigen, because this provided a highly
sensitive readout for CD8⫹ T cell immunity caused by the
efficacy with which the SIINFEKL peptide from OVA is
presented on H-2Kb MHC class I molecules. EL4 or CD1dhiEL4 tumor cells were exposed to an osmotic shock in the
presence of 10 mg/ml OVA protein (resulting in ⵑ100 ng
OVA protein per 106 cells, as measured by ELISA; Morinaga
Institute of Biological Science, Inc.). To monitor the processing and presentation of the tumor cells on MHC class I
and II, we first adoptively transferred CFSE-labeled OT-I
and OT-II OVA-specific TCR transgenic T cells as reporters,
and then injected 2 ⫻ 106 ␣-GalCer–loaded EL4(OVA) or
CD1dhi-EL4(OVA) cells (Fig. 4 A, top). The injection of
tumor cells induced strong proliferation in both CD4⫹ and
CD8⫹ T cells, and the up-regulation of the CD25 high affinity receptor for IL-2 (mean of CD25⫹-proliferated T cells ⫽
1.65, 22.65, 2.74, and 59.8% in EL4(OVA), EL4(OVA)/Gal,
CD1dhi-EL4(OVA), and CD1dhi-EL4(OVA)/Gal, respectively;
Fig. 4 A, top). For CD8⫹ OT-I cells, stimulation of cell division was dependent on the presence of transporter associated
with antigen presentation (TAP) molecules in the recipient mice
(Fig. 4 A, bottom). This indicates that injected EL4(OVA)
cells were cross-presented by TAP-expressing antigen-presenting cells in the host. To implicate DCs during crosspresentation, we depleted DCs using a transgenic mouse in
which the CD11c promoter drives expression of the diphtheria toxin receptor (DTR); this allows depletion of CD11crich DCs after injection of DT and eliminates cross-presentation

immunized and challenged as indicated in the diagram (n ⫽ 5 B16 or EL4; n ⫽ 9 tumor/Gal-B16 –EL4). Data are means ⫾ SEM. Similar results were
obtained in two independent experiments.
JEM VOL. 204, October 29, 2007
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Vaccination with B16/Gal i.v. induces T cells specific
for defined melanoma differentiation antigens
Another manifestation of the weak immunogenicity of B16
melanoma is the difficulty in detecting responses to defined
melanoma antigens by ELISPOT and intracellular cytokine
staining assays. However, when we injected CD1dhi-B16/Gal
tumor cells and looked for CD8⫹ T cells specific for melanoma antigens 1 wk later, we could detect IFN-␥–producing
cells responsive to several different MHC class I–binding,
nonamer peptides; these included peptides from the gp100,
tryrosinase-related, and dopachrome tautomerase (DCT)/
tyrosinase-related protein 2 (TRP-2) antigens (Fig. 2 A, left)
(17, 18). Some of these cytokine-producing T cells persisted
for 4 wk (Fig. 2 A, right). After immunization with B16/Gal,
we also detected IFN-␥–producing CD8⫹ cells, but in smaller
numbers than CD1dhi-B16/Gal (Fig. 2 A). We additionally
documented TRP-2–specific, CD8⫹ T cells using an intracellular cytokine staining assay after injection of B16/Gal or
CD1dhi-B16/Gal but not tumor cells lacking ␣-GalCer (0.16 ⫾
0.04, 0.22 ⫾ 0.06, and ⱕ0.05 in B16/Gal, CD1dhi-B16/Gal,
and others, respectively; Fig. 2 B). Again, even if we completely deleted NK1.1⫹ cells by anti-NK1.1 antibody treatment 3 and 5 d after vaccination, T cell immunity developed
to tumor/Gal; however, if we deleted NK1.1⫹ cells before
immunization, T cell immunity was almost abolished (Fig. 2 C).
These results indicate that once T cell immunity was initiated, the mice no longer needed NK1.1⫹ cells. The detection
of melanoma-specific CD8⫹ T cell responses with a single
dose of ␣-GalCer–modified tumor cells was of some interest
given previous difficulties in eliciting immunity to this particular tumor.

challenged the mice with tumor cells injected s.c. but without any loading with ␣-GalCer. In each case, the mice were
resistant to s.c. challenge of the original tumor, which was
otherwise lethal (Fig. 3 B). We also vaccinated WT, CD4⫺/⫺,
and CD8⫺/⫺ mice with 5 ⫻ 105 CD1dhi-EL4/Gal i.v. and
challenged the mice 2 wk later s.c. with 2 ⫻ 105 parental
EL4 tumor cells; the WT mice were immune, but the T cell–
depleted mice were not (Fig. S2, available at http://www
.jem.org/cgi/content/full/jem.20070458/DC1). In the case
of B16, we rechallenged the mice with B16 or EL4 at 12 mo
after rejecting tumor. Again, such mice showed the protection against B16 tumors but not EL4 tumors, indicating the
establishment of protective long-term memory in a tumorspecific manner (Fig. 3 C). We likewise observed protection
for 1 yr when we vaccinated with CD1dhi-J558/Gal tumor
(Fig. S3). Therefore, several tumors can induce resistance
when exposed to ␣-GalCer and injected i.v. in relatively low
doses into mice.
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Figure 4. DCs are less effective than tumor/Gal in presenting OVA antigen when injected via the i.v. route. (A) Mice were adoptively transferred with 2 ⫻ 106 CFSE-labeled OT-I cells and were immunized the next day with EL4(OVA) or CD1dhi-EL4(OVA) ⫾ Gal. 3 d later, the animals were tested
for proliferation of transferred OT-I cells as well as CD25 (top). Data are representative of two separate experiments (n ⫽ 2 per group). Different strains
of C57BL/6 mice (bottom) were adoptively transferred with 2 ⫻ 106 CFSE-labeled OT-I cells or OT-II T cells and then challenged with 2 ⫻ 106 CD1dhiEL4(OVA)/Gal cells i.v. 3 d later, cell proliferation was monitored in the spleen by CFSE dilution (bottom). Naive indicates OT-I or OT-II cell-transferred, but
not immunized, mice. The numbers indicate CD25⫹ (top) or CD25⫺ (bottom) differentiated OT-I cells. Data are representative of three separate experiments (n ⫽ 3 per group). (B) As in A, but now the immune response was measured in naive and immunized mice using H-2Kb/OVA tetramers 7 d later.
Mice were injected i.v. with 2 ⫻ 106 BM-derived DCs that had been pulsed with 1 M OVA257–264 peptide in the absence or presence of 100 ng/ml
␣-GalCer. The expansion of OVA-specific CD8⫹ T cells was compared with different forms of 2 ⫻ 106 EL4 tumors that were loaded with OVA (see Materials
and methods) in the absence or presence of ␣-GalCer. Data are representative of four separate experiments (n ⫽ 4 per group). (C) The expansion of OVAspecific CD8⫹ T cells was shown. Mice were immunized with 100 g OVA peptide per mouse with or without 1 g of free ␣-GalCer i.v. per mouse (reference 20). Data are representative of four separate experiments (n ⫽ 4 per group). Gated cells in B and C indicate CD8⫹ Kb/OVA257–264⫹ double-positive
cells using Kb/OVA257–264 tetramer–PE and CD8-FITC. (D) As in B, but the immune response was measured with an intracellular cytokine staining. 7 d after
immunization, spleen cells were cultured with or without OVA257–264 peptide to stimulate OVA-specific CD8⫹ T cells for 6 h, and T cell production of IFN-␥ was
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DCs capture tumor cells after i.v. injection of tumor/Gal
To begin to understand the immunogenicity of co-stimulator–
poor tumor/Gal, we pursued previous findings that CD8␣⫹
DCs in mouse spleen captured dying cells when the latter
were administered by the i.v. route (8). We reasoned that
killing of the injected tumor/Gal tumor by NKT and NK
cells would provide a source of dying tumor for DCs. We
first verified that CD8␣⫹ DCs were able to capture allogeneic

spleen cells injected i.v., because allogeneic cells are killed by
NK cells (8) (Fig. S5, available at http://www.jem.org/cgi/
content/full/jem.20070458/DC1). Then, to follow uptake
of the tumor cells, we performed experiments with CFSElabeled EL4 tumor rather than B16 at first, because higher
doses of tumor cells are needed to detect tumor cell uptake by
FACS and B16 is toxic when ⵑ106 cells are given i.v. By flow
cytometry and confocal microscopy, we observed that CD8␣⫹
DCs picked up the injected CFSE-labeled live CD1dhi-EL4/
Gal 10 h later (CFSE-positive cells from total CD11c⫹ DCs ⫽
3.38 ⫾ 0.39% and ⬍0.01% in CD1dhi-EL4/Gal–injected
mice and naive C57BL/6 mice, respectively; Fig. 5, A–C).
When uptake kinetics were followed, the DCs in WT mice
had CFSE⫹ debris for at least 24 h after tumor/Gal administration, but not in J␣18⫺/⫺ mice (Fig. 5, C and D). We
interpret these findings to indicate that the presentation of
␣-GalCer on tumor cells leads to killing by NKT and/or NK
cells, followed by uptake by CD8␣⫹ DCs.
DC maturation in response to ␣-GalCer–loaded tumor
cells i.v.
To explain the T cell response to injected tumor/Gal, we reasoned that the DCs capturing tumor had to be undergoing
differentiation or maturation. We initially examined several
cell-surface molecules after injecting tumor/Gal (Fig. 6 and
Fig. S6, available at http://www.jem.org/cgi/content/full/
jem.20070458/DC1). CD86 expression on both CD8␣⫹ and
CD8␣⫺ subsets of DCs began to increase within hours of
injecting CD1dhi-B16/Gal (tumor/Gal; Fig. 6 A). We also observed up-regulation of CD40 and CD80 and down-regulation
of CD119 (Fig. S6), which are characteristic changes for DCs
undergoing maturation in vivo (9). To assess DCs in other tissues, we compared spleen with lung and liver, and again there
was a clear increase in CD86 expression if we injected tumor/
Gal as opposed to native tumor (Fig. 6 B, compare filled and
open tracings). The increase in CD86 expression after the injection of ␣-GalCer–loaded tumor was similar to that seen
with free ␣-GalCer (Fig. 6 B), a particularly powerful stimulus
for DC maturation (9, 21, 22), indicating that tumor/Gal
were surprisingly able to mimic the agonistic glycolipid itself.
Another manifestation of maturation is that DCs start to
produce protective cytokines like IL-12. In fact, IL-12 was
induced within 4 h of giving mice B16/Gal or CD1dhi-B16/
Gal i.v. but not tumor cells without ␣-GalCer (Fig. 6 C,
compare left and right panels). To establish the need for NKT
cells to bring about DC maturation, we assessed cell-surface
markers and IL-12 production by DCs in J␣18⫺/⫺ mice given
tumor/Gal. Both signs of maturation were ablated in the absence of NKT cells (IL-12p40/p70–positive CD8⫹ cells from

measured by intracellular cytokine staining. Data are means ⫾ SEM obtained from five mice per group in three independent experiments. *, P ⬍ 0.05 for
EL4(OVA)/G or CD1dhi-EL4(OVA)/G versus the other groups and EL4(OVA)/G versus CD1dhi-EL4(OVA)/G). (E) J␣18⫺/⫺, CD4⫺/⫺, TAP⫺/⫺, or CD40⫺/⫺ mice
were used as recipients for CD1dhi-EL4(OVA)/Gal, and the immune responses were tested by intracellular cytokine staining in the absence or presence of
OVA peptide 1 wk later. Data are means ⫾ SEM obtained from five mice per group in three independent experiments. *, P ⬍ 0.05 for WT versus J␣18⫺/⫺,
TAP⫺/⫺, or CD40⫺/⫺; P ⬎ 0.05 for WT versus CD4⫺/⫺.
JEM VOL. 204, October 29, 2007
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of many forms of antigen (19). Treatment with DT totally
ablated the presentation of OVA from the injected tumor
cells to OT-I and OT-II transgenic T cells (Fig. 4 A). These results indicate that DCs cross-present antigens from ␣-GalCer–
loaded EL4 thymoma cells.
We next studied the CD8⫹ T cell response in naive mice,
i.e., in the absence of transferred transgenic T cells. Much
stronger responses to DCs were noted when we used the more
standard s.c. route of DC administration (Fig. S4, available at
http://www.jem.org/cgi/content/full/jem.20070458/DC1).
However, DCs coated with peptide with or without ␣-GalCer
were poorly immunogenic when given by the i.v. as well
as the s.c. route (Fig. 4, B and D; and Fig. S4). In contrast,
EL4(OVA) tumor cells induced stronger immunity if the cells
were loaded with ␣-GalCer and injected i.v. (Fig. 4, B and D),
but not when given s.c. The OVA immune responses could
be observed by measuring the numbers of OVA-specific
CD8⫹ T cells with H-2Kb/OVA tetramers (tetramer-positive CD8⫹ T cells ⫽ 0.59 ⫾ 0.16, 0.38 ⫾ 0.21, 0.52 ⫾
0.01, 3.03 ⫾ 0.61, 0.44 ⫾ 0.16, 7.71 ⫾ 1.62, and 0.11 ⫾
0.06 in DC-pep–, DC-pep/G–, EL4(OVA)-, EL4(OVA)/
Gal-, CD1dhi-EL4(OVA)–, and CD1dhi-EL4(OVA)/Gal–
injected mice and naive C57BL/6 mice, respectively; Fig.
4 B) or with intracellular cytokine staining for IFN-␥ production (Fig. 4 D). The response to tumor/Gal was entirely
dependent on the presence of V␣14⫹ NKT cells, TAP, and
CD40, as indicated with the appropriate knockout mice (Fig.
4 E). Silk et al. previously reported on immune responses to
the combination of peptide and ␣-GalCer given i.v. (20),
so we repeated their protocol with 100 g OVA peptide as
a model antigen plus ␣-GalCer. We detected just 0.49 ⫾
0.19% tetramer-positive CD8⫹ T cells in the spleen, which
was 20 times smaller than we observed when we injected
CD1dhi-EL4(OVA)/Gal into mice i.v. (tetramer-positive CD8⫹
T cells ⫽ 0.03 ⫾ 0.02 and 0.49 ⫾ 0.19 in OVApep- and
OVApep plus Gal–injected mice, respectively; Fig. 4 C).
These data indicate that tumor/Gal are more immunogenic
than DCs if the i.v. route of immunization is used, but that
immunity requires V␣14⫹NKT cells and TAP⫹ DCs in the
recipient mice.

CD11c⫹ DCs ⫽ 1.96 ⫾ 0.23, 2.7 ⫾ 0.26, 2.58 ⫾ 0.23, 5.4 ⫾
0.36, 7.9 ⫾ 0.39, and 8.14 ⫾ 0.5 in naive C57BL/6 and
B16-, CD1dhi-B16–, Gal-, B16/Gal-, and CD1dhi-B16/Gal–
injected mice, respectively, and 1.95 ⫾ 0.73, 2.43 ⫾ 0.31,
and 2.37 ⫾ 0.21 in naive J␣18⫺/⫺ and B16/Gal- and CD1dhiB16/Gal–injected J␣18⫺/⫺ mice, respectively; Fig. 6, C–E).
These data indicate that DCs begin to mature quickly upon
injection of tumor/Gal and suggest that DCs must be capturing
glycolipid for presentation to NKT cells, a known mediator
of DC maturation (9, 21).
To understand how NKT cells might be mobilized to
mature the splenic DCs, we considered the possibility that
DCs were cross-presenting glycolipid from phagocytosed
tumor/Gal. We therefore isolated CD11c⫹ DCs and CD11c⫺
non-DCs from mice injected with tumor/Gal. The CD11c⫹
DCs were selectively able to elicit IFN-␥ secretion from liver
mononuclear cells (MNCs), an enriched source of primary
NKT cells (Fig. 6 F). In fact, liver MNCs from J␣18⫺/⫺ mice
that lacked NKT cells did not respond to the DCs (Fig. 6 F,
compare shaded and open bars). To document cross-presentation of ␣-GalCer from the injected tumor cells, we repeated
the experiments with CD1d⫺/⫺ mice in which only the injected tumor cells expressed CD1d. Now the DCs were unable to cross-present the glycolipid to NKT cells (Fig. 6 F).
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Collectively, these results indicate that DCs cross-present
glycolipid after i.v. injection of tumor/Gal in a CD1d-dependent manner.
DCs are needed to elicit adaptive immunity to an injection
of tumor/Gal
The data in Figs. 5 and 6 indicated that DCs were both taking
up tumor/Gal and undergoing NKT cell–dependent maturation in vivo, but to prove that these two events were responsible
for adaptive T cell immunity, we did two additional experiments. First, we injected CD1dhi-B16/Gal tumor cells and
isolated CD11c⫹ and CD11c− cells from the mice 10 h later.
We then transferred each population to naive mice and looked
for CD8⫹ T cells specific for melanoma antigens 1 wk later. We
were able to detect IFN-␥–producing CD8⫹ T cells in response
to trp2 and gp100 peptide in CD11c⫹ cell–transferred mice but
not CD11c⫺ cell–transferred mice (Fig. 7 A). We also injected
CD1dhi-B16/Gal i.v. into CD11c-DTR transgenic mice,
which allowed for the depletion of the antigen-capturing DCs
after the injection of DT 1 d later, as previously described (19).
Treatment with DT totally ablated presentation of trp2 or gp100
peptides from the injected tumor cells to the T cells (Fig. 7 B).
These experiments indicate that DCs play a major role in the
capture and presentation of tumor/Gal to T cells.
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Figure 5. Maturing DCs capture tumor/Gal after i.v. injection. (A–C) 10 million CFSE-labeled CD1dhi-EL4 with or without loading with ␣-GalCer
were injected into C57BL/6 mice. (A, left) Gated areas indicate subsets of CD11c⫹ DCs, CD8␣⫹ DCs, and CD8␣⫺ DCs. (right) The frequency of uptake of
CFSE⫹ tumor cells by CD11c⫹ splenic DCs was measured by flow cytometry. (B) CD11c cells were enriched by MACS for analysis by confocal microscopy
after injection of CFSE-labeled live CD1dhi-EL4/Gal cells. (i) Tumor fragments (green), (ii) CD86 to detect mature DCs (red), (iii) DAPI nuclear stain (blue),
and (iv) a merged image are shown. Bar, 10 m. The data in A and B are representative of three independent experiments (n ⫽ 3 per group). (C) The mean
percentage of DCs taking up CFSE-labeled tumor debris at the indicated time points is shown. (D) As in C, but antigen capture by mature DCs at 10 h was
quantified in CD1dhi-B16 ⫾ Gal injected with WT C57BL/6 or J␣18⫺/⫺ mice. All data in C and D are means ⫾ SEM obtained from three mice per indicated
time point in two independent experiments per each group.
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DISCUSSION
Tumors are typically poorly immunogenic, in part because
most tumors fail to express co-stimulatory molecules that are
needed to induce adaptive T cell immunity. Tumor cells provide an impetus to identify principles that lead to stronger
JEM VOL. 204, October 29, 2007

adaptive immunity in vivo. The new approach in this study
surprisingly begins with several different mouse tumors as the
only source of tumor antigen, but the tumor cells are loaded with
an agonistic glycolipid for NKT cells, ␣-GalCer (tumor/Gal).
When relatively low doses of tumor/Gal are injected i.v., we
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Figure 6. In vivo maturation of DCs and cross-presentation of ␣-GalCer in DCs after administration of tumor/Gal. (A) Spleen cells were obtained at 0, 2, 4, and 6 h after administration of CD1dhi-B16/Gal. Low density spleen cells were stained with anti-CD11c–PE and CD8␣-FITC (to identify
DCs and their CD8⫹ or CD8⫺ subsets) and with biotinylated isotype control or CD86 mAb, followed by streptavidin-allophycocyanin. (B) As in A, but DCs
were tested in three different organs for CD86 expression 6 h after injecting the tumor cells indicated on the left. All data in A, B, and D are representative of two independent experiments (n ⫽ 2 per group). (C) Splenic DCs were analyzed by intracellular cytokine staining for IL-12p40 4 h after immunization with tumor/Gal, followed by 4 h of culture in brefeldin A. DCs were identified with CD11c-allophycocyanin and CD8␣-FITC and were subsequently
fixed and stained with PE-conjugated anti–IL-12p40 mAb. (D and E) DC maturation studies, as in A and C, were performed in WT and J␣18⫺/⫺ mice to
show the NKT cell dependence. Numbers in C and E indicate the percentage of IL-12–producing cells in CD8⫹ or CD8⫺ subsets of CD11c⫹ DCs, and all
data are representative of three independent experiments (n ⫽ 3 per group). (F) To evaluate the cross-presentation of ␣-GalCer derived from tumor/Gal,
DCs or non-DCs were isolated by CD11c magnetic beads at 10 h after injecting 5 ⫻ 105 CD1dhi-B16/Gal into WT C57BL/6 or CD1d⫺/⫺ mice. 105 APCs per
well were co-cultured with 105 liver MNCs per well from C57BL/6 or J␣18⫺/⫺ mice for 48 h. Then, the IFN-␥ from the supernatants was measured by
ELISA. All data are means ⫾ SEM obtained from three independent experiments (n ⫽ 5 per group). *, P ⬍ 0.05 for WT versus J␣18⫺/⫺ for liver MNCs;
**, P ⬍ 0.01 for WT versus CD1d⫺/⫺ for APCs.

find that it becomes possible to harness many of the different
types of lymphocytes that can resist cancer: innate NKT and
NK cells and adaptive CD4⫹ and CD8⫹ T cells.
The use of tumor/Gal (either live or irradiated tumor
cells) leads to antitumor resistance that seems more effective
than previous methods (6, 7, 23). First, immunity is induced
to four different poorly immunogenic tumors that we have
tested. Second, we only administer a single low dose of ⬍1
million tumor cells. Third, we measure CD8⫹ T cell immunity to several melanocyte differentiation antigens, again with
a single dose of B16 tumor. Fourth, the immunity is long
lived and requires both CD4⫹ and CD8⫹ T cells.
A critical feature of tumor cells coated with glycolipid is
that they are active in stimulating NKT and NK lymphocytes
if given by the i.v. route (11). As previously noted, NKT cells
are able to recognize and resist tumor/Gal that are injected
i.v., even tumors lacking co-stimulatory molecules such as
CD40, CD80, or CD86. In contrast, these molecules are required to initiate responses by polyclonal T cells that recognize
peptides presented on MHC products. After the resistance of
tumor/Gal by NKT and NK cells, some of the killed tumor
cells are captured by DCs, and glycolipids also are presented
on CD1d molecules to additional NKT cells. This leads to
IL-12 production from DCs, most likely through the expression
of CD40L that occurs within 4 h of activation of NKT cells
(22). The IL-12 further mobilizes NK cells in vivo (24).
Importantly, the maturing DCs are then able to mobilize the
adaptive T cell limb of immunity, resulting in long-term T cell
resistance to the tumor.
The pivotal step in inducing adaptive immunity to tumor/
Gal is the capture and cross-presentation of glycolipid by
DCs in vivo. We have observed that DCs from CD1d⫺/⫺
mice are unable to present tumor/Gal to NKT cells, indicating that DCs have to cross-present glycolipid from the tumor
cells on CD1d, a process that has been reported by Wu et al.
in tissue culture (10). The ensuing presentation of glycolipid
by DCs to NKT cells is one of the most potent known means
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to induce DC differentiation or maturation (9, 21, 22), and it
is more effective in vivo than other stimuli such as Toll-like
receptor ligands and CD40 ligation (7).
This new pathway to enhanced antitumor immunity differs from immunogenic cell death that takes place with certain chemotherapies (6). In the latter instance, dying tumor
cells are recognized by DCs and also provide high mobility
group box 1 to mature the DCs, whereas in the system described in this paper, the tumor cells become immunogenic
because of cross-presentation of glycolipid to NKT cells,
which in turn leads to DC maturation. NKT cell–based DC
maturation seems more potent than high mobility group
box 1–based maturation, because higher percentages of animals resist tumor challenge, the resistance is longer lived,
and protection can be exerted on highly tumorigenic transplantable tumors.
In effect, the injection of glycolipid-loaded tumor cells
harnesses four of the major components responsible for the
immunogenicity of antigen-capturing DCs: (a) antigens gain
access to DCs for antigen processing to take place; (b) the DCs
mature, including heightened expression of co-stimulatory
molecules and production of IL-12; (c) the DCs are localized
in lymphoid tissues in a position to select antigen-reactive
T cells; and (d) the DEC⫹ CD8⫹ subset of DCs that crosspresents peptides to CD8⫹ T cells is engaged. We have confirmed, using EL4 tumor cells, that the DEC-205⫹ CD8⫹
subset of DCs cross-presents antigens on MHC class I products (25, 26).
Previous observations have shown that innate NK cells
can amplify MuLV antigen-specific T cell immunity using
CD70 gene–transduced RMA tumor cells (27). It is possible
that the NK cells were being mobilized by the CD70-transduced tumor cells, leading to the killing, uptake, and maturation of DCs, as shown in this study.
We would like to propose that the experiments in this
paper should be extended into patients with malignancy,
particularly hematologic malignancies or malignancies with
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Figure 7. DCs are required for inducing immunity to tumor/Gal. (A) 10 h after injecting CD1dhi-B16/Gal tumor cells, CD11c⫹ and CD11c− cells were
isolated, and 3 ⫻ 106 CD11c⫹ and 5 ⫻ 106 CD11c− cells were transferred to naive C57BL/6 mice; spleen cells from uninjected mice served as the negative
control. 1 wk later, we measured CD8⫹ T cells specific for melanoma antigens (trp2 and gp100) by ELISPOT assay. (B) 1 d after injecting CD1dhi-B16/Gal i.v.
into CD11c-DTR transgenic mice, CD11c⫹ DCs were depleted with DT. 7 d later, we analyzed antigen-specific T cell responses to trp2 or gp100 peptides by
ELISPOT assays. All data are means obtained from two independent experiments (n ⫽ 5 per group). *, P ⬍ 0.05 for CD11c+ transferred mice versus others
(left) and DT-treated CD11c-DTR mice versus immunized WT mice (right). SFC, spot-forming cells.
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MATERIALS AND METHODS
Reagents. ␣−GalCer was synthesized at the Institute of Physical and Chemical Research. ␣−GalCer and vehicle (0.4% DMSO) were diluted in PBS.
This concentration of DMSO by itself did not elicit innate or adaptive immunity to tumors. LPS-free OVA was obtained from Seikagaku Corp. The
following mAbs were purchased from BD Biosciences: anti–mouse CD1d
(1B1), CD8␣ (53-6.7), CD11c (HL3), CD19 (1D3), CD25 (PC61), CD44
(IM7), CD62L (MEL-14), CD40 (3/23), CD70 (FR70), CD80 (16-10A1),
CD86 (B7-2), CD119 (GR20), CD154 (MR1), NK1.1(PK136), TCR␤
(H57-597), V␣2 TCR (B20.1), H-2Kb (AF16-88.5), I-Ab(KH74), IFN-␥
(XMG1.2), IL-4 (11B11), and IL-12p40/p70 (C15.6) and mouse IgG1
(A85-1). Biotinylated mAbs were detected with streptavidin-allophycocyanin.
For flow cytometry of OVA257–264 peptide (SIINFEKL)–specific CD8 T cells,
we used H-2Kb OVA tetramer–SIINFEKL–PE (Beckman Coulter). For
analysis, we used a flow cytometer (FACSCalibur; BD Biosceinces) and
CELLQuest (BD Biosciences) or FlowJo (Tree Star, Inc.) software.
Cell preparation. DCs were generated from bone marrow progenitors, as
previously described (34). On day 6, 100 ng/ml ␣-GalCer was added to
DCs for 40 h, and 100 ng/ml LPS was added for the last 16 h to mature the
DCs. Tumor cells were also cultured for 48 h with 500 ng/ml ␣-GalCer to
load them with glycolipid. These ␣-GalCer–loaded cells were washed three
times before injection. To isolate NKT cell–enriched MNCs, livers were
teased into a single suspension, resuspended in a 40/60% Percoll solution
(GE Healthcare), and centrifuged for 20 min at 900 g to float the MNCs.
To enrich DCs from liver and lung, we digested them with collagenase
and again floated the DCs on Percoll gradients (35). Before collagenase
treatement, lungs were perfused with 5 ml of ice-cold PBS and removed. In
some experiments, splenic DCs were isolated using CD11c magnetic beads
(Miltenyi Biotec).
Mice and cell lines. Pathogen-free C57BL/6 (B6) and BALB/c female
mice at 6–8 wk old were purchased from CLEA Japan, and B6 CD4⫺/⫺,
CD8⫺/⫺, CD40⫺/⫺, TAP⫺/⫺, and MHC II⫺/⫺ (B6.129-H2dlAbl-Ea) mice
were purchased from the Jackson Laboratory. B6 CD1d⫺/⫺ and J␣18⫺/⫺
mice have been previously described (11, 36). OT-I and OT-II TCR transgenic mice (B6 background) were provided by W. Heath (Walter and Eliza
Hall Institute of Medical Research, Melbourne, Australia). B6 CD11cDTR/GFP transgenic mice were a gift of D. Littman (New York University, New York, NY) and were backcrossed 12 generations to C57BL/6. All
mice were maintained under specific pathogen-free conditions and studied
in compliance with institutional guidelines. B16, EL4, and J558 cell lines
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were obtained from the American Type Culture Collection, and WEHI-3B
cells were obtained from the Institute for Fermentation. As previously described, for stable introduction of CD1d, pMX-mCD1d-IRES-GFP–carrying mCD1d was retrovirally transduced into tumor cells by lipofection, and
cells were subsequently sorted based on the expression of GFP by FACSVantage (BD Biosciences) (11).
Immune assays and in vivo tumor studies. Mice were immunized i.v.
with tumor/Gal. In experiments for evaluation of adaptive immunity, immunized mice were challenged with parental tumor cells s.c. For immune
assays, we used 2 mice per group and performed two to four experiments;
for tumor growth curves, we used 5–10 mice per group and performed two
experiments. Tumor size was measured every 2 d.
Assays for priming of antigen-specific T cell immunity. To identify
antigen-specific T cells for OVA, spleen cells were isolated 7 d after immunization with OVA carrying tumor cells or OVA peptide–pulsed cells and
challenged in culture for 6 h in the presence or absence of 1 M OVA257–264
peptide (SIINFEKL, for CD8⫹ T cells) or 10 M OVA323–339 peptide
(ISQAVHAAHAEINEAGR, for CD4⫹ T cells) with brefeldin A. The cells
were then stained for cell-surface markers, FITC-conjugated anti-CD4 or
anti-CD8 mAb, fixed with Cytofix/Cytoperm Plus permeabilization (BD
Biosciences), and stained with PE-conjugated anti–IFN-␥ mAb. ELISPOT
assays for melanoma antigen–specific IFN-␥–secreting cells were performed
on 96-well filtration plates (Millipore) coated with rat anti–mouse IFN-␥
capture antibody at 10 g/ml (BD Biosciences), as previously described (17).
CD8⫹ T cells from spleen cells were purified by positive selection and were
incubated with Trp2180–188 (SVYDFFVWL; Kb) or gp10025–33 (EGSRNQDWL; Db), Tyrp455–463 (TAPDNLGYA; Db), Tyrp522–529 (YAEDYEEL; Kb),
or Dct363–371(SQVMNLHNL; Db) peptide-pulsed CD11c⫹ spleen DCs
for 36 h. Biotinylated anti–mouse IFN-␥ detection antibody was added
at 2 g/ml (BD Biosciences) for 2 h, and spots were developed with an
avidin–peroxidase complex (Vectastain Elite Kit; Vector Laboratories) and
stable diaminobenzidine substrate (Research Genetics), and were counted
microscopically.
Assays for capture of tumor antigens by DCs in vivo. DC capture of
CFSE-labeled tumor cells in vivo was assessed directly by FACS by gating on
CD11c⫹ spleen cells. We assessed CFSE labeling of CD11c⫹CD8␣⫹ and
CD11c⫹CD8␣⫺ DC subsets, as well as reactivity with antibodies to DC
maturation markers like CD86. Results were verified by confocal microscopy to look for uptake of CFSE-labeled fragments into the DCs. The cytosmears were fixed for 10 min at room temperature in 4% paraformaldehyde
in PBS. Cells were stained with anti-biotin–CD86 mAb and streptavidin–
Alexa Fluor 547 (Invitrogen), and DNA was labeled with DAPI. Cells were
visualized by confocal microscopy (Leica).
Assays for antigen presentation in vivo using OVA as a surrogate
antigen. To assess the capacity of tumor/Gal to induce T cell–mediated
immunity, we treated tumor cells with osmotic shock in the presence of
10 mg/ml OVA protein in hypertonic medium and subsequently treated
with hypotonic medium; such tumor cells, when injected i.v., are actively
captured and processed by DCs (8, 9). Using this approach, T cell responses
were monitored with 2 ⫻ 106 CFSE-labeled, CD8⫹ (OT-I), and CD4⫹
(OT-II) OVA-specific TCR transgenic T cells. The EL4(OVA) tumor cells
were loaded with ␣-GalCer for 2 d before osmotic shock with OVA protein.
2 ⫻ 106 EL4(OVA)/Gal or other controls were given i.v. 1 d after adoptive
transfer of the OVA-specific TCR transgenic T cells. Spleen cells were
tested 3 d later to monitor T cell proliferation based on dilution of the CFSE
signal. OT-I and OT-II T cells were identified by the expression of CD8 or
CD4 and V␣2 and evaluated for the up-regulation of CD25 or CD44 and
the down-regulation of CD62L. In some experiments, to assess host DC
presentation of cell-associated antigens to T cells, CD11c-DTR mice after
treatment with DT (Sigma-Aldrich) (19) and TAP⫺/⫺ and CD40⫺/⫺ mice
were used as recipients.
2651

Downloaded from http://rupress.org/jem/article-pdf/204/11/2641/1003413/jem_20070458.pdf by Rockefeller University user on 17 August 2020

tumor-rich pleural effusions and ascites, in which tumor cells
are readily available for loading with appropriate glycolipids.
Some human tumor cells express CD1d and are able to present endogenous glycolipids as well as ␣-GalCer to NKT
cells, eliciting IFN-␥ release and cytolysis (28, 29). The glycolipid ␣-GalCer, although it has not yet been used extensively, has shown safety in humans (30–32). Irradiated tumor
cells, when coated with glycolipid, were active in our experiments, so that a patient’s tumor cells could be subject to ionizing irradiation to block tumor growth. A critical unknown
is the type of tumor cells that should be injected, because
cancer stem cells or cancer-initiating cells (33) may well represent the pivotal targets for immune-based resistance to
malignancy. Research in patients will be required to test
tumor cells that have been coated with a glycolipid agonist
for NKT cells as a means to energize several types of tumorreactive lymphocytes and several fundamental immunogenic
features of DCs.

Statistical analysis. Differences in survival of treatment groups were analyzed using the log-rank test. Differences were analyzed using the MannWhitney U test. P ⬍ 0.05 was considered statistically significant.
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